UNASSIGNED: Purpose To assess the potential utility of an integrin avb3-targeting radiotracer, technetium 99m-PEG4-E[PEG4-cyclo(arginine-glycine-aspartic acid-D-phenylalanine- @entity376 )]2 ( @entity69377 ), for single photon emission computed tomography (SPECT)/computed tomography (CT) for monitoring of the progression and prognosis of @entity1575 in a @entity35 model. Materials and Methods All animal experiments were performed by following the protocol approved by the institutional animal care and use committee. @entity69377 was prepared and longitudinal SPECT/CT was performed to monitor the progression (n = 8) and recovery (n = 5) of @entity1575 induced in a @entity35 model by means of @entity7008 ( @entity2796 ) administration. The mean liver-to-background radioactivity per unit volume ratio was analyzed for comparisons between the @entity2796 and control (saline) groups at different stages of @entity1575 . Data were compared by using Student t and Mann-Whitney tests. Results of SPECT/CT were compared with those of ex vivo biodistribution analysis (n = 5). Results Accumulation of @entity69377 in the liver increased in proportion to the progression of @entity82 and @entity2796 exposure time; accumulation levels were significantly different between the @entity2796 and control groups as early as week 4 of @entity2796 administration (liver-to-background ratio: 32.30    3.39 vs 19.01    3.31; P = .0002). Results of ex vivo immunofluorescence staining demonstrated the positive expression of integrin avb3 on the activated hepatic stellate cells, and the integrin avb3 levels in the liver corresponded to the results of SPECT/CT (R(2) = 0.75, P < .0001). @entity69377 uptake in the fibrotic liver decreased after antifibrotic therapy with interferon a2b compared with that in the control group (relative liver-to-background ratio: 0.45    0.05 vs 1.01    0.05; P < .0001) or spontaneous recovery (relative liver-to-background ratio: 0.56    0.06 vs 1.01    0.05; P < .0001). Conclusion (99m)Tc-3PRGD2 SPECT/CT was successfully used to monitor the progression and recovery of @entity1575 and shows potential applications for noninvasive diagnosis of early stage @entity1575 . (  ) RSNA, 2015 Online supplemental material is available for this article.

Small-Animal SPECT/CT of the Progression and Recovery of @entity35 XXXX by Using an Integrin avb3-targeting Radiotracer.

@entity2796 :: ('CHEBI:32497', 'Chemical') :: ['TAA'] @entity7008 :: ('MESH:D013853', 'Chemical') :: ['thioacetamide'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity69377 :: ('MESH:C561921', 'Chemical') :: ['(99m)Tc-3PRGD2'] @entity376 :: ('CHEBI:25094', 'Chemical') :: ['lysine'] @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver fibrosis']
@entity1575 :: (MESH:D008103,Disease) :: ['Liver Fibrosis']
